文献速递妇科

法妥珠单抗联合化疗对比安慰剂联合化疗在低CA-125铂敏感卵巢癌中的随机II期试验

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2023-02-07

本研究为随机II期试验,纳入214例低CA-125(≤3倍正常上限,105 U/mL)铂敏感首次复发性高级别浆液性卵巢癌患者,按2:1随机接受法妥珠单抗或安慰剂联合标准化疗。主要终点无进展生存期(PFS)在两组间无显著差异(单侧α=0.10;P=0.25;HR=0.89,80%CI:0.71,1.11),中位PFS分别为11.7个月与10.8个月。结论认为在标准化疗基础上加法妥珠单抗未改善PFS,且本研究未检测叶酸受体-α表达。

要点

  • 法妥珠单抗联合化疗组与安慰剂联合化疗组的中位PFS分别为11.7个月与10.8个月,差异无统计学意义(HR=0.89,80%CI:0.71,1.11;P=0.25)。
  • 法妥珠单抗联合化疗未发现新的安全性问题。
  • 本研究未检测叶酸受体-α表达。

核心结论

  • 在低CA-125水平、铂敏感首次复发性卵巢癌患者中,标准化疗联合法妥珠单抗未改善无进展生存期。
  • 本研究未检测叶酸受体-α表达。

研究设计与样本

  • 随机II期试验,纳入214例低CA-125(≤3倍正常上限,105 U/mL)铂敏感首次复发性高级别浆液性卵巢癌患者,按2:1随机分配至法妥珠单抗联合化疗组(142例)或安慰剂联合化疗组(72例)。
  • 患者接受研究者选择的卡铂/紫杉醇每3周方案或卡铂/聚乙二醇脂质体多柔比星每4周方案共6个周期,联合法妥珠单抗(5 mg/kg每周)或安慰剂,维持治疗至疾病进展或不耐受。

主要发现

  • 主要疗效终点PFS在两组间无显著差异(单侧α=0.10;P=0.25;HR=0.89,80%CI:0.71,1.11)。
  • 法妥珠单抗联合化疗组中位PFS为11.7个月(95%CI:10.2,13.6),安慰剂联合化疗组为10.8个月(95%CI:9.5,13.2)。
  • 法妥珠单抗联合化疗未发现新的安全性问题。

关键数值与推荐

  • 入组条件包括CA-125≤3倍正常上限(105 U/mL)、高级别浆液性、铂敏感复发性卵巢癌、既往接受过减瘤手术和一线铂类化疗、首次复发距一线铂类治疗6至36个月。
  • 法妥珠单抗剂量为5 mg/kg每周,联合化疗或作为维持治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究未检测叶酸受体-α表达。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The primary purpose of this study was to determine if farletuzumab, an antifolate receptor-α monoclonal antibody, improved progression-free survival (PFS) versus placebo when added to standard chemotherapy regimens in patients with platinum-sensitive recurrent ovarian cancer (OC) in first relapse (platinum-free interval: 6-36 months) with low cancer antigen 125 (CA-125) levels. METHODS: Eligibility included CA-125 ≤ 3 x upper limit of normal (ULN, 105 U/mL), high-grade serous, platinum-sensitive recurrent OC, previous treatment with debulking surgery, and first-line platinum-based chemotherapy with 1st recurrence between 6 and 36 months since frontline platinum-based treatment. Patients received investigator's choice of either carboplatin (CARBO)/paclitaxel (PTX) every 3 weeks or CARBO/pegylated liposomal doxorubicin (PLD) every 4 weeks x6 cycles in combination with either farletuzumab [5 mg/kg weekly] or placebo randomized in a 2:1 ratio. Maintenance treatment with farletuzumab (5 mg/kg weekly) or placebo was given until disease progression or intolerance. RESULTS: 214 patients were randomly assigned to farletuzumab+chemotherapy (142 patients) versus placebo+chemotherapy (72 patients). The primary efficacy endpoint, PFS, was not significantly different between treatment groups (1-sided α = 0.10; p-value = 0.25; hazard ratio [HR] = 0.89, 80% confidence interval [CI]: 0.71, 1.11), a median of 11.7 months (95% CI: 10.2, 13.6) versus 10.8 months (95% CI: 9.5, 13.2) for farletuzumab+chemotherapy and placebo+chemotherapy, respectively. No new safety concerns were identified with the combination of farletuzumab+chemotherapy. CONCLUSIONS: Adding farletuzumab to standard chemotherapy does not improve PFS in patients with OC who were platinum-sensitive in first relapse with low CA-125 levels. Folate receptor-α expression was not measured in this study. (Clinical Trial Registry NCT02289950).

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Herzog TJ, Pignata S, Ghamande SA, et al. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. Gynecol Oncol. 2023. PMID: 36758420. doi:10.1016/j.ygyno.2023.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。